Rofecoxib and Clinically Significant Upper and Lower GI Events Revisited based on documents from recent litigation.

摘要

BackgroundBased on published data, it is widely believed and cited that rofecoxib use is associated with approximately a 50% reduction in significant gastrointestinal complications such as bleeding.